Biodistribution and radiation dosimetry of the anti-HER2 Affibody molecule 68Ga-ABY-025 in breast cancer patients

Mattias Sandström, Karolina Lindskog, Irina Velikyan, Anders Wennborg, Joachim Feldwisch, Dan Sandberg, Vladimir Tolmachev, Anna Orlova, Jens Sörensen, Jörgen Carlsson, Henrik Lindman, Mark Lubberink

Research output: Contribution to journalArticlepeer-review

48 Citations (Scopus)


68Ga-ABY-025 is a radiolabeled Affibody molecule for in vivo diagnosis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer tumors with PET. The aim of the present work was to measure the biodistribution and estimate the radiation dosimetry of 68Ga-ABY-025 for 2 different peptide mass doses in a single group of patients using dynamic and serial whole-body PET/CT. Methods: Eight patients with metastatic breast cancer were included. Each patient underwent an abdominal 45-min dynamic and 3 whole-body PET/CT scans at 1, 2, and 4 h after injection of a low peptide dose (LD) and a high peptide dose (HD), with approximately the same amount of radioactivity, in separate investigations 1 wk apart. As input to the absorbed dose calculations, volumes of interest were drawn on all clearly identifiable source organs: liver, kidneys, spleen, descending aorta, and upper large intestine. Absorbed doses were calculated using OLINDA/EXM, version 1.1. Results: Of the major organs, the highest radionuclide uptake at 1, 2, and 4 h after injection was observed in the kidneys and liver. The highest absorbed organ doses were seen in the kidneys, followed by the liver for both LD and HD 68Ga-ABY-025. Absorbed doses to liver and kidneys were slightly but significantly higher for LD. Total effective dose was 0.030 ± 0.003 mSv/MBq for LD and 0.028 ± 0.002 mSv/MBq for HD. Conclusion: The effective dose for a typical 200-MBq administration of 68Ga-ABY-025 is 6.0 mSv for LD and 5.6 mSv for HD. Therefore, from a radiation dosimetry point of view, HD is preferred for PET/CT evaluation of HER2-expressing breast cancer tumors. These effective doses are somewhat higher than earlier published values for other 68Ga-labeled tracers, such as 0.021 ± 0.003 mSv/MBq for 68Ga-DOTATATE and 68Ga-DOTATOC, mainly because of higher uptake in liver and kidney.

Original languageEnglish
Pages (from-to)867-871
Number of pages5
JournalJournal of Nuclear Medicine
Issue number6
Publication statusPublished - 1 Jun 2016
Externally publishedYes


  • Ga-gallium
  • Affibody
  • Breast cancer metastases
  • Dosimetry
  • HER2-receptor

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Biodistribution and radiation dosimetry of the anti-HER2 Affibody molecule <sup>68</sup>Ga-ABY-025 in breast cancer patients'. Together they form a unique fingerprint.

Cite this